Renal Transplantasyon Uygulanan Hastalarda İmmünsupresif Tedavinin Monitorizasyonu

1. Kaplan B, Meier-Kriesche HU: Renal transplantation: A half
century of success and the long road ahead. J Am Soc Nephrol
2004;15:3270-3271
2. USRDS 2004 annual data report. Am J Kidney Dis 2005;45:
8–280
3. Kaplan B: Overcoming barriers to long-term graft survival. Am J
Kidney Dis 2006;47(4 Suppl 2):52-64
4. Djamali A, Samaniego M, Muth B, Muehrer R, Hofmann RM,
Pirsch J, Howard A, Mourad G, Becker BN: Medical care of
kidney transplant recipients after the first posttransplant year. Clin
J Am Soc Nephrol. 2006;1:623-640
5. Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM,
Gaston RS, Roth D, Scandling JD, Singer GG. Recommendations
for the outpatient surveillance of renal transplant recipients.
American Society of Transplantation. J Am Soc Nephrol 2000;11
Suppl 15:1-86.
6. Sindhi R, LaVia MF, Paulling E, McMichael J, Burckart G, Shaw
S, Sindhi LA, Livingston R, Sehgal S, Jaffe J: Stimulated response
of peripheral lymphocytes may distinguish cyclosporine effect in
renal transplant recipients receiving a cyclosporine+rapamycin
regimen. Transplantation 2000;69:432-436
7. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL: Cyclosporin:
an updated review of the pharmacokinetic properties, clinical
efficacy and tolerability of a microemulsion-based formulation
(neoral)1 in organ transplantation. Drugs 2001;61:1957-2016
8. Hariharan S. Recommendations for outpatient monitoring of
kidney transplant recipients. Am J Kidney Dis. 2006;47(4 Suppl
2):S22-36.
9. Levy G, Thervet E, Lake J, Uchida K: Consensus on Neoral
C(2): Expert Review in Transplantation (CONCERT) Group.
Patient management by Neoral C(2) monitoring: an international
consensus statement. Transplantation. 2002;15;73(9 Suppl):12-8
10. Astellas Pharma US Inc: Prograf Package Insert. Deerfield, IL,
Astellas Pharma US Inc, 2005
11. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M:
Cyclosporine-associated chronic nephropathy. N Engl J Med
1984;311:699-705
12. Keown PA, Stiller CR, Ulan RA, Sinclair NR, Wall WJ: Carruthers
G, Howson W. Immunological and pharmacological monitoring in
the clinical use of cyclosporin A. Lancet 198;1:686-689
13. Kasiske BL, Heim-Duthoy K, Rao KV, Awni WM: The relationship
between cyclosporine pharmacokinetic parameters and subsequent
acute rejection in renal transplant recipients. Transplantation
1988;46:716-722
14. Holt DW, Johnston A: [In Process Citation] BioDrugs 1997; 7:175-
197
15. Barone G, Chang CT, Choc MG Jr, Klein JB, Marsh CL, Meligeni
JA, Min DI, Pescovitz MD, Pollak R, Pruett TL, Stinson JB,
Thompson JS, Vasquez E, Waid T, Wombolt DG, Wong RL: The
pharmacokinetics of a microemulsion formulation of cyclosporine
in primary renal allograft recipients. The Neoral Study Group.
Transplantation 1996;61:875-880
16. Keown P, Niese D: Cyclosporine microemulsion increases drug
exposure and reduces acute rejection without incremental toxicity
in de novo renal transplantation. International Sandimmun Neoral
Study Group. Kidney Int 1998;54:938-944
17. Cole E, Keown P, Landsberg D, Halloran P, Shoker A, Rush D,
Jeffrey J, Russell D, Stiller C, Muirhead N, Paul L, Zaltzman J,
Loertscher R, Daloze P, Dandavino R, Boucher A, Handa P, Lawen
J, Belitsky P, Parfrey P, Tan A, Hendricks L: Safety and tolerability
of cyclosporine and cyclosporine microemulsion during 18 months
of follow-up in stable renal transplant recipients: a report of the
Canadian Neoral Renal Study Group. Transplantation 1998;65:505-
510
18. Mahalati K, Belitsky P, West K, Kiberd B, Fraser A, Sketris I,
Macdonald AS, McAlister V, Lawen J: Approaching the therapeutic
window for cyclosporine in kidney transplantation: a prospective
study. J Am Soc Nephrol 2001;12:828-833
19. Mahalati K, Belitsky P, Sketris I, West K, Panek R: Neoral
monitoring by simplified sparse sampling area under the
concentration-time curve: its relationship to acute rejection and
cyclosporine nephrotoxicity early after kidney transplantation.
Transplantation 1999;68:55-62
20. Keown P, Landsberg D, Halloran P, Shoker A, Rush D, Jeffery
J, Russell D, Stiller C, Muirhead N, Cole E, Paul L, Zaltzman J,
Loertscher R, Daloze P, Dandavino R, Boucher A, Handa P, Lawen
J, Belitsky P, Parfrey P: A randomized, prospective multicenter
pharmacoepidemiologic study of cyclosporine microemulsion in
stable renal graft recipients. Report of the Canadian Neoral Renal
Transplantation Study Group. Transplantation 1996;62:1744-1752
21. Clase CM, Mahalati K, Kiberd BA, Lawen JG, West KA, Fraser
AD, Belitsky P: Adequate early cyclosporin exposure is critical to
prevent renal allograft rejection: patients monitored by absorption
profiling. Am J Transplant 2002;2:789-795
KIRKPANTUR: Renal Transplantasyon Sonrası İmmunsupresif Tedavi
Cilt/Vol. 18, No, 1, 2009 Sayfa/Page 35-47
44
Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
Turkish Nephrology, Dialysis and Transplantation Journal
45
22. International Neoral Renal Transplantation Study Group Am J
Transplant 2: 148–156, 2002
23. Cole E, Midtvedt K, Johnston A, Pattison J, O’Grady C:
Recommendations for the implementation of Neoral C(2)
monitoring in clinical practice. Transplantation 2002;73(9
Suppl):19-22
24. Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG: Aspeslet
L, Metrakos P. Comparison of neoral dose monitoring with
cyclosporine through levels versus 2-hr postdose levels in stable
liver transplant patients. Transplantation 1998;66:1621-1627
25. Keown PA, Kiberd B, Balshaw R, Khorasheh S, Marra C: Belitsky
P, Kalo Z. An economic model of 2-hour post-dose ciclosporin
monitoring in renal transplantation. Pharmacoeconomics
2004;22:621-632
26. Bîrsan T, Loinig C, Bodingbauer M, Wekerle T, Rockenschaub
S, Berlakovich G, Soliman T, Mühlbacher F, Steininger R:
Comparison between C0 and C2 monitoring in de novo renal
transplant recipients: retrospective analysis of a single-center
experience. Transplantation 2004;78:1787-1791
27. Kyllönen LE, Salmela KT: Early cyclosporine C0 and C2 monitoring
in de novo kidney transplant patients: a prospective randomized
single-center pilot study. Transplantation 2006;81:1010-1015
28. Nashan B, Cole E, Levy G, Thervet E: Clinical validation studies
of Neoral C(2) monitoring: a review. Transplantation 2002;73(9
Suppl):3-11
29. Schiff J, Cole E, Cantarovich M: Therapeutic monitoring of
calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol
2007;2:374-384
30. Pascual M, Curtis J, Delmonico FL, Farrell ML, Williams WW
Jr, Kalil R, Jones P, Cosimi AB, Tolkoff-Rubin N: A prospective,
randomized clinical trial of cyclosporine reduction in stable patients
greater than 12 months after renal transplantation. Transplantation
2003;75:1501-1505
31. Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD,
Chapman JR: The natural history of chronic allograft nephropathy.
N Engl J Med 2003;349:2326-2333
32. Citterio F, Scatà MC, Borzi MT, Pozzetto U, Castagneto M:C2
single-point sampling to evaluate cyclosporine exposure in longterm
renal transplant recipients. Transplant Proc 2001;33:3133-
3136
33. Rowshani AT, Scholten EM, Bemelman F, Eikmans M, Idu M,
Roos-van Groningen MC, Surachno JS, Mallat MJ, Paul LC, de
Fijter JW, Bajema IM, ten Berge I, Florquin S: No difference in
degree of interstitial Sirius red-stained area in serial biopsies from
area under concentration-over-time curves-guided cyclosporine
versus tacrolimus-treated renal transplant recipients at one year. J
Am Soc Nephrol 2006;17:305-312
34. Scott LJ, McKeage K, Keam SJ, Plosker GL: Tacrolimus: a further
update of its use in the management of organ transplantation.
Drugs 2003;63(12):1247-1297
35. Hoogtanders K, van der Heijden J, Christiaans M, van de Plas
A, van Hooff J, Stolk L: Dried blood spot measurement of
tacrolimus is promising for patient monitoring. Transplantation
2007;27;83(2):237-238
36. Wong KM, Shek CC, Chau KF, Li CS: Abbreviated tacrolimus
area-under-the-curve monitoring for renal transplant recipients.
Am J Kidney Dis 2000;35:660-666
37. Armendáriz Y, Pou L, Cantarell C, Lopez R, Perelló M, Capdevila
L: Evaluation of a limited sampling strategy to estimate area under
the curve of tacrolimus in adult renal transplant patients. Ther
Drug Monit 2005;27:431-434
38. Scholten EM, Cremers SC, Schoemaker RC, Rowshani AT, van
Kan EJ, den Hartigh J, Paul LC, de Fijter JW: AUC-guided dosing
of tacrolimus prevents progressive systemic overexposure in renal
transplant recipients. Kidney Int 2005;67:2440-2447
39. Balbontin FG, Kiberd B, Squires J, Singh D, Fraser A, Belitsky
P, Lawen J: Tacrolimus monitoring by simplified sparse sampling
under the concentration time curve. Transplant Proc. 2003;35:2445-
2448
40. Undre NA, van Hooff J, Christiaans M, Vanrenterghem Y, Donck
J, Heeman U, Kohnle M, Zanker B, Land W, Morales JM, Andrés
A, Schäfer A, Stevenson P: Low systemic exposure to tacrolimus
correlates with acute rejection. Transplant Proc 1999;31:296-298
41. Kershner RP, Fitzsimmons WE: Relationship of FK506 whole
blood concentrations and efficacy and toxicity after liver and
kidney transplantation. Transplantation 1996;62: 920–926
42. Hardinger KL, Bohl DL, Schnitzler MA, Lockwood M, Storch
GA, Brennan DC: A randomized, prospective, pharmacoeconomic
trial of tacrolimus versus cyclosporine in combination with
Thymoglobulin in renal transplant recipients. Transplantation
2005;80: 41–46
43. Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti P, Mariat
C, Margreiter R, Capdevilla L, Lang P, Vialtel P, Ortuno-Mirete
J, Charpentier B, Legendre C, Sanchez-Plumed J, Oppenheimer
F, Kessler M: Corticosteroid-free immunosuppression with
tacrolimus, mycophenolate mofetil, and daclizumab induction in
renal transplantation. Transplantation 2005;79: 807–814
44. Alloway R, Steinberg S, Khalil K, Gourishankar S, Miller J,
Norman D, Hariharan S, Pirsch J, Matas A, Zaltzman J, Wisemandle
K, Fitzsimmons W, First MR: Two years postconversion from a
prograf-based regimen to a once-daily tacrolimus extended-release
formulation in stable kidney transplant recipients. Transplantation
2007;83:1648-1651
45. Chueh SC, Kahan BD: Clinical application of sirolimus in renal
transplantation: an update. Transpl Int 2005;18:261-277
46. Vitko S, Tedesco H, Eris J, Pascual J, Whelchel J, Magee JC,
Campbell S, Civati G, Bourbigot B, Alves Filho G, Leone J, Garcia
VD, Rigotti P, Esmeraldo R, Cambi V, Haas T, Jappe A, Bernhardt
P, Geissler J, Cretin N: Everolimus with optimized cyclosporine
dosing in renal transplant recipients: 6-month safety and efficacy
results of two randomized studies. Am J Transplant 2004;4:626-
635
47. Ferreira AN, Machado PG, Felipe CR, Motegi SA, Hosaka
BH, Tanaka MK, Kamura LA, Park SI, Garcia R, Franco M,
Alfieri F, Casarini DE, Tedesco-Silva H Jr: Medina-Pestana
JO. Concentration-controlled use of sirolimus associated with
reduced exposure of cyclosporine in black recipients of primarily
living renal allograft donors: 12-month results. Clin Transplant
2005;19:607-615
48. Yatscoff RW, Aspeslet LJ, Gallant HL. Pharmacodynamic
monitoring of immunosuppressive drugs. Clin Chem 1998;44:428-
432
49. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics:
monogenic inheritance of erythrocyte thiopurine methyltransferase
activity. Am J Hum Genet 1980;32:651-662
50. Chocair PR, Duley JA, Simmonds HA, Cameron JS: The importance
of thiopurine methyltransferase activity for the use of azathioprine
in transplant recipients. Transplantation 1992;53:1051-1056
51. Soria-Royer C, Legendre C, Mircheva J, Premel S, Beaune P, Kreis
H: Thiopurine-methyl-transferase activity to assess azathioprine
myelotoxicity in renal transplant recipients. Lancet 1993;341:1593-
1594
KIRKPANTUR: Renal Transplantasyon Sonrası İmmunsupresif Tedavi
Cilt/Vol. 18, No, 1, 2009 Sayfa/Page 35-47
Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
Turkish Nephrology, Dialysis and Transplantation Journal
52. Mircheva J, Legendre C, Soria-Royer C, Thervet E, Beaune P,
Kreis H: Monitoring of azathioprine-induced immunosuppression
with thiopurine methyltransferase activity in kidney transplant
recipients. Transplantation 1995;60:639-642
53. Bergan S, Rugstad HE, Bentdal O, Stokke O: Monitoring
of azathioprine treatment by determination of 6-thioguanine
nucleotide concentrations in erythrocytes. Transplantation. 1994;
58:803-808
54. Bergan S, Rugstad HE, Bentdal O, Sødal G, Hartmann A, Leivestad
T, Stokke O: Monitored high-dose azathioprine treatment reduces
acute rejection episodes after renal transplantation. Transplantation
1998;66:334-339
55. Bullingham RE, Nicholls AJ, Kamm BR: Clinical pharmacokinetics
of mycophenolate mofetil. Clin Pharmacokinet 1998;34:429-455
56. Wieland E, Shipkova M, Schellhaas U, Schütz E, Niedmann PD,
Armstrong VW, Oellerich M: Induction of cytokine release by the
acyl glucuronide of mycophenolic acid: a link to side effects? Clin
Biochem 2000;33:107-113
57. Westley IS, Brogan LR, Morris RG, Evans AM, Sallustio BC:
Role of Mrp2 in the hepatic disposition of mycophenolic acid and
its glucuronide metabolites: effect of cyclosporine. Drug Metab
Dispos. 2006;34:261-266
58. Nowak I, Shaw LM: Mycophenolic acid binding to human serum
albumin: characterization and relation to pharmacodynamics. Clin
Chem 1995;41:1011-1017
59. Meier-Kriesche HU, Shaw LM, Korecka M, Kaplan B:
Pharmacokinetics of mycophenolic acid in renal insufficiency.
Ther Drug Monit 2000;22:27-30
60. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls
O, Zimmerhackl LB, Oellerich M, Tönshoff B: Comparison of the
Emit immunoassay with HPLC for therapeutic drug monitoring
of mycophenolic acid in pediatric renal-transplant recipients on
mycophenolate mofetil therapy. Clin Chem 2002;48:517-525
61. van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok
RD, van Gelder T: Explaining variability in mycophenolic acid
exposure to optimize mycophenolate mofetil dosing: A population
pharmacokinetic meta-analysis of mycophenolic acid in renal
transplant recipients. J Am Soc Nephrol 2006;17:871-880
62. Kuypers DR, Vanrenterghem Y, Squifflet JP, Mourad M,
Abramowicz D, Oellerich M, Armstrong V, Shipkova M, Daems
J: Twelve-month evaluation of the clinical pharmacokinetics of
total and free mycophenolic acid and its glucuronide metabolites
in renal allograft recipients on low dose tacrolimus in combination
with mycophenolate mofetil. Ther Drug Monit 2003;25:609-622
63. Glander P, Hambach P, Braun KP, Fritsche L, Giessing M, Mai
I, Einecke G, Waiser J, Neumayer HH, Budde K: Pre-transplant
inosine monophosphate dehydrogenase activity is associated
with clinical outcome after renal transplantation. Am J Transplant
2004;4:2045-51
64. Shipkova M, Armstrong VW, Oellerich M, Wieland E: Acyl
glucuronide drug metabolites: toxicological and analytical
implications. Ther Drug Monit 2003;25:1-16
65. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz
E, Mehls O, Zimmerhackl LB, Oellerich M, Tönshoff B: The
pharmacokinetic-pharmacodynamic relationship for total and free
mycophenolic Acid in pediatric renal transplant recipients: A report
of the german study group on mycophenolate mofetil therapy. J
Am Soc Nephrol 2002;13:759-768
66. Oellerich M, Shipkova M, Schütz E, Wieland E, Weber L, Tönshoff
B, Armstrong VW: Pharmacokinetic and metabolic investigations of
mycophenolic acid in pediatric patients after renal transplantation:
implications for therapeutic drug monitoring. German Study Group
on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant
Recipients. Ther Drug Monit 2000;22:20-26
67. Hale MD, Nicholls AJ, Bullingham RE, Hené R, Hoitsma
A, Squifflet JP, Weimar W, Vanrenterghem Y, Van de Woude
FJ, Verpooten GA: The pharmacokinetic-pharmacodynamic
relationship for mycophenolate mofetil in renal transplantation.
Clin Pharmacol Ther 1998;64:672-683
68. Cox VC, Ensom MH: Mycophenolate mofetil for solid organ
transplantation: does the evidence support the need for clinical
pharmacokinetic monitoring? Ther Drug Monit 2003;25:137-157
69. Pillans PI, Rigby RJ, Kubler P, Willis C, Salm P, Tett SE, Taylor
PJ: A retrospective analysis of mycophenolic acid and cyclosporin
concentrations with acute rejection in renal transplant recipients.
Clin Biochem 2001;34:77-81
70. Shaw LM, Korecka M, Aradhye S, Grossman R, Bayer L,
Innes C, Cucciara A, Barker C, Naji A, Nicholls A, Brayman
K: Mycophenolic acid area under the curve values in African
American and Caucasian renal transplant patients are comparable.
J Clin Pharmacol 2000;40:624-633
71. Yau WP, Vathsala A, Lou HX, Chan E: Is a standard fixed dose
of mycophenolate mofetil ideal for all patients? Nephrol Dial
Transplant 2007;22:3638-3645
72. Schütz E, Shipkova M, Armstrong VW, Niedmann PD, Weber L,
Tönshoff B, Pethig K, Wahlers T, Braun F, Ringe B, Oellerich M:
Therapeutic drug monitoring of mycophenolic acid: comparison of
HPLC and immunoassay reveals new MPA metabolites. Transplant
Proc 1998;30:1185-1187
73. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de
Fijter JW, Squifflet JP, Hené RJ, Verpooten GA, Navarro MT, Hale
MD, Nicholls AJ: A randomized double-blind, multicenter plasma
concentration controlled study of the safety and efficacy of oral
mycophenolate mofetil for the prevention of acute rejection after
kidney transplantation. Transplantation 1999;68(2):261-266
74. van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D,
Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Toenshoff B,
Mamelok RD: Therapeutic drug monitoring of mycophenolate
mofetil in transplantation. Ther Drug Monit 2006;28:145-154
75. Kaplan B, Gruber SA, Nallamathou R, Katz SM, Shaw LM:
Decreased protein binding of mycophenolic acid associated with
leukopenia in a pancreas transplant recipient with renal failure.
Transplantation 1998;65:1127-1129
76. Kiberd BA, Lawen J, Fraser AD, Keough-Ryan T, Belitsky P:
Early adequate mycophenolic acid exposure is associated with less
rejection in kidney transplantation. Am J Transplant 2004;4:1079-
1083
77. van Hest R, Mathot R, Vulto A, Weimar W, van Gelder T: Predicting
the usefulness of therapeutic drug monitoring of mycophenolic
acid: a computer simulation. Ther Drug Monit 2005;27(2):163-
167
78. Willis C, Taylor PJ, Salm P, Tett SE, Pillans PI: Evaluation of
limited sampling strategies for estimation of 12-hour mycophenolic
acid area under the plasma concentration-time curve in adult renal
transplant patients. Ther Drug Monit 2000;22:549-554
KIRKPANTUR: Renal Transplantasyon Sonrası İmmunsupresif Tedavi
Cilt/Vol. 18, No, 1, 2009 Sayfa/Page 35-47
46
Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
Turkish Nephrology, Dialysis and Transplantation Journal
47
79. Borrows R, Chusney G, Loucaidou M, James A, Lee J, Tromp
JV, Owen J, Cairns T, Griffith M, Hakim N, McLean A, Palmer
A, Papalois V, Taube D: Mycophenolic acid 12-h trough level
monitoring in renal transplantation: association with acute rejection
and toxicity. Am J Transplant 2006;6:121-128
80. Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W,
Oppenheimer F, Maca J, Hall M: The ERL B301 Study Groups.
Enteric-coated mycophenolate sodium is therapeutically equivalent
to mycophenolate mofetil in de novo renal transplant patients. Am
J Transplant 2004;4:231-236
81. Cattaneo D, Cortinovis M, Baldelli S, Bitto A, Gotti E, Remuzzi
G, Perico N: Pharmacokinetics of mycophenolate sodium and
comparison with the mofetil formulation in stable kidney transplant
recipients. Clin J Am Soc Nephrol 2007;2:1147-1155
82. Shaw LM, Figurski M, Milone MC, Trofe J, Bloom RD:
Therapeutic drug monitoring of mycophenolic acid. Clin J Am Soc
Nephrol 2007;2:1062-1072
83. Gaston RS: Current and evolving immunosuppressive regimens in
kidney transplantation. Am J Kidney Dis 2006;47(4 Suppl 2):3-21
84. Wyeth Pharmaceuticals Inc: Rapamune Package Insert.
Philadelphia: PA,Wyeth Pharmaceuticals Inc, 2005
85. Johnson RW, Kreis H, Oberbauer R, Brattström C, Claesson K,
Eris J: Sirolimus allows early cyclosporine withdrawal in renal
transplantation resulting in improved renal function and lower
blood pressure. Transplantation 2001;72:777-786
86. Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz
JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman
J, Burke JT: Rapamune Maintenance Regimen Study Group.
Long-term improvement in renal function with sirolimus after
early cyclosporine withdrawal in renal transplant recipients:
2-year results of the Rapamune Maintenance Regimen Study.
Transplantation 2003;76:364-370
87. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena
FP, Burke JT, Brault Y, Gioud-Paquet M, Scarola JA, Neylan JF:
Rapamune Maintenance Regimen Trial. Long-term benefits with
sirolimus-based therapy after early cyclosporine withdrawal. J Am
Soc Nephrol 2004;15(3):809-817
88. Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen
J, Russ G, Grinyó JM, Stallone G, Hartmann A, Pinto JR, Chapman
J, Burke JT, Brault Y, Neylan JF: Rapamune Maintenance Regimen
Study Group. Early cyclosporine withdrawal from a sirolimusbased
regimen results in better renal allograft survival and renal
function at 48 months after transplantation. Transpl Int 2005;18:22-
28
89. Diekmann F, Campistol JM: Conversion from calcineurin inhibitors
to sirolimus in chronic allograft nephropathy: benefits and risks.
Nephrol Dial Transplant 2006;1:562-568
90. Leogrande D, Teutonico A, Ranieri E, Saldarelli M, Gesualdo L,
Schena FP, Di Paolo S: Monitoring biological action of rapamycin
in renal transplantation. Am J Kidney Dis 2007;50:314-325
91. Di Paolo S, Teutonico A, Ranieri E, Gesualdo L, Schena PF:
Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma.
Am J Kidney Dis 2007;49:462-470
92. Letavernier E, Bruneval P, Mandet C, Van Huyen JP, Péraldi
MN, Helal I, Noël LH, Legendre C. High sirolimus levels may
induce focal segmental glomerulosclerosis de novo. Clin J Am Soc
Nephrol 2007;2:326-333
93. Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, Rouilly
M, Gerbeau C, Cambon N, Boger R, Rordorf C: Everolimus Phase
2 Study Group. Longitudinal assessment of everolimus in de
novo renal transplant recipients over the first post-transplant year:
pharmacokinetics, exposure-response relationships, and influence
on cyclosporine. Clin Pharmacol Ther 2001;69:48-56
94. Neumayer HH, Paradis K, Korn A, Jean C, Fritsche L, Budde K,
Winkler M, Kliem V, Pichlmayr R, Hauser IA, Burkhardt K, Lison
AE, Barndt I: Appel-Dingemanse S. Entry-into-human study with
the novel immunosuppressant SDZ RAD in stable renal transplant
recipients. Br J Clin Pharmacol 1999;48:694-703
95. Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF: Sirolimus
increases transforming growth factor-beta1 expression and
potentiates chronic cyclosporine nephrotoxicity. Kidney Int
2004;65:1262-1271
96. Kovarik JM, Kaplan B, Tedesco Silva H, Kahan BD, Dantal J,
Vitko S, Boger R, Rordorf C: Exposure-response relationships
for everolimus in de novo kidney transplantation: defining a
therapeutic range. Transplantation 2002;73:920-925
97. Lorber MI, Ponticelli C, Whelchel J, Mayer HW, Kovarik J, Li Y,
Schmidli H: Therapeutic drug monitoring for everolimus in kidney
transplantation using 12-month exposure, efficacy, and safety data.
Clin Transplant 2005;19:145-152
98. Romagnoli J, Citterio F, Favi E, Salerno MP, Tondolo V, Spagnoletti
G, Renna R, Castagneto M. Higher incidence of acute rejection
in renal transplant recipients with low everolimus exposure.
Transplant Proc 2007;39:1823-1836
99. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T: 156
Study Group. Everolimus and reduced-exposure cyclosporine in de
novo renal-transplant recipients: a three-year phase II, randomized,
multicenter, open-label study. Transplantation 2004;78:1332-1340
100. Pascual J, Marcén R, Ortuño J: Clinical experience with everolimus
(Certican): optimizing dose and tolerability. Transplantation
2005;79(9 Suppl):80-84